Cargando…
Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
BACKGROUND AND OBJECTIVE: Dysferlinopathies are a group of muscle disorders caused by mutations in the DYSF gene. Previous muscle imaging studies describe a selective pattern of muscle involvement in smaller patient cohorts, but a large imaging study across the entire spectrum of the dysferlinopathi...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166612/ https://www.ncbi.nlm.nih.gov/pubmed/29735511 http://dx.doi.org/10.1136/jnnp-2017-317488 |
_version_ | 1783360073091776512 |
---|---|
author | Diaz-Manera, Jordi Fernandez-Torron, Roberto LLauger, Jaume James, Meredith K Mayhew, Anna Smith, Fiona E Moore, Ursula R Blamire, Andrew M Carlier, Pierre G Rufibach, Laura Mittal, Plavi Eagle, Michelle Jacobs, Marni Hodgson, Tim Wallace, Dorothy Ward, Louise Smith, Mark Stramare, Roberto Rampado, Alessandro Sato, Noriko Tamaru, Takeshi Harwick, Bruce Rico Gala, Susana Turk, Suna Coppenrath, Eva M Foster, Glenn Bendahan, David Le Fur, Yann Fricke, Stanley T Otero, Hansel Foster, Sheryl L Peduto, Anthony Sawyer, Anne Marie Hilsden, Heather Lochmuller, Hanns Grieben, Ulrike Spuler, Simone Tesi Rocha, Carolina Day, John W Jones, Kristi J Bharucha-Goebel, Diana X Salort-Campana, Emmanuelle Harms, Matthew Pestronk, Alan Krause, Sabine Schreiber-Katz, Olivia Walter, Maggie C Paradas, Carmen Hogrel, Jean-Yves Stojkovic, Tanya Takeda, Shin’ichi Mori-Yoshimura, Madoka Bravver, Elena Sparks, Susan Bello, Luca Semplicini, Claudio Pegoraro, Elena Mendell, Jerry R Bushby, Kate Straub, Volker |
author_facet | Diaz-Manera, Jordi Fernandez-Torron, Roberto LLauger, Jaume James, Meredith K Mayhew, Anna Smith, Fiona E Moore, Ursula R Blamire, Andrew M Carlier, Pierre G Rufibach, Laura Mittal, Plavi Eagle, Michelle Jacobs, Marni Hodgson, Tim Wallace, Dorothy Ward, Louise Smith, Mark Stramare, Roberto Rampado, Alessandro Sato, Noriko Tamaru, Takeshi Harwick, Bruce Rico Gala, Susana Turk, Suna Coppenrath, Eva M Foster, Glenn Bendahan, David Le Fur, Yann Fricke, Stanley T Otero, Hansel Foster, Sheryl L Peduto, Anthony Sawyer, Anne Marie Hilsden, Heather Lochmuller, Hanns Grieben, Ulrike Spuler, Simone Tesi Rocha, Carolina Day, John W Jones, Kristi J Bharucha-Goebel, Diana X Salort-Campana, Emmanuelle Harms, Matthew Pestronk, Alan Krause, Sabine Schreiber-Katz, Olivia Walter, Maggie C Paradas, Carmen Hogrel, Jean-Yves Stojkovic, Tanya Takeda, Shin’ichi Mori-Yoshimura, Madoka Bravver, Elena Sparks, Susan Bello, Luca Semplicini, Claudio Pegoraro, Elena Mendell, Jerry R Bushby, Kate Straub, Volker |
author_sort | Diaz-Manera, Jordi |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Dysferlinopathies are a group of muscle disorders caused by mutations in the DYSF gene. Previous muscle imaging studies describe a selective pattern of muscle involvement in smaller patient cohorts, but a large imaging study across the entire spectrum of the dysferlinopathies had not been performed and previous imaging findings were not correlated with functional tests. METHODS: We present cross-sectional T1-weighted muscle MRI data from 182 patients with genetically confirmed dysferlinopathies. We have analysed the pattern of muscles involved in the disease using hierarchical analysis and presented it as heatmaps. Results of the MRI scans have been correlated with relevant functional tests for each region of the body analysed. RESULTS: In 181 of the 182 patients scanned, we observed muscle pathology on T1-weighted images, with the gastrocnemius medialis and the soleus being the most commonly affected muscles. A similar pattern of involvement was identified in most patients regardless of their clinical presentation. Increased muscle pathology on MRI correlated positively with disease duration and functional impairment. CONCLUSIONS: The information generated by this study is of high diagnostic value and important for clinical trial development. We have been able to describe a pattern that can be considered as characteristic of dysferlinopathy. We have defined the natural history of the disease from a radiological point of view. These results enabled the identification of the most relevant regions of interest for quantitative MRI in longitudinal studies, such as clinical trials. CLINICAL TRIAL REGISTRATION: NCT01676077. |
format | Online Article Text |
id | pubmed-6166612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-61666122018-10-04 Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials Diaz-Manera, Jordi Fernandez-Torron, Roberto LLauger, Jaume James, Meredith K Mayhew, Anna Smith, Fiona E Moore, Ursula R Blamire, Andrew M Carlier, Pierre G Rufibach, Laura Mittal, Plavi Eagle, Michelle Jacobs, Marni Hodgson, Tim Wallace, Dorothy Ward, Louise Smith, Mark Stramare, Roberto Rampado, Alessandro Sato, Noriko Tamaru, Takeshi Harwick, Bruce Rico Gala, Susana Turk, Suna Coppenrath, Eva M Foster, Glenn Bendahan, David Le Fur, Yann Fricke, Stanley T Otero, Hansel Foster, Sheryl L Peduto, Anthony Sawyer, Anne Marie Hilsden, Heather Lochmuller, Hanns Grieben, Ulrike Spuler, Simone Tesi Rocha, Carolina Day, John W Jones, Kristi J Bharucha-Goebel, Diana X Salort-Campana, Emmanuelle Harms, Matthew Pestronk, Alan Krause, Sabine Schreiber-Katz, Olivia Walter, Maggie C Paradas, Carmen Hogrel, Jean-Yves Stojkovic, Tanya Takeda, Shin’ichi Mori-Yoshimura, Madoka Bravver, Elena Sparks, Susan Bello, Luca Semplicini, Claudio Pegoraro, Elena Mendell, Jerry R Bushby, Kate Straub, Volker J Neurol Neurosurg Psychiatry Neuromuscular BACKGROUND AND OBJECTIVE: Dysferlinopathies are a group of muscle disorders caused by mutations in the DYSF gene. Previous muscle imaging studies describe a selective pattern of muscle involvement in smaller patient cohorts, but a large imaging study across the entire spectrum of the dysferlinopathies had not been performed and previous imaging findings were not correlated with functional tests. METHODS: We present cross-sectional T1-weighted muscle MRI data from 182 patients with genetically confirmed dysferlinopathies. We have analysed the pattern of muscles involved in the disease using hierarchical analysis and presented it as heatmaps. Results of the MRI scans have been correlated with relevant functional tests for each region of the body analysed. RESULTS: In 181 of the 182 patients scanned, we observed muscle pathology on T1-weighted images, with the gastrocnemius medialis and the soleus being the most commonly affected muscles. A similar pattern of involvement was identified in most patients regardless of their clinical presentation. Increased muscle pathology on MRI correlated positively with disease duration and functional impairment. CONCLUSIONS: The information generated by this study is of high diagnostic value and important for clinical trial development. We have been able to describe a pattern that can be considered as characteristic of dysferlinopathy. We have defined the natural history of the disease from a radiological point of view. These results enabled the identification of the most relevant regions of interest for quantitative MRI in longitudinal studies, such as clinical trials. CLINICAL TRIAL REGISTRATION: NCT01676077. BMJ Publishing Group 2018-10 2018-05-07 /pmc/articles/PMC6166612/ /pubmed/29735511 http://dx.doi.org/10.1136/jnnp-2017-317488 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Neuromuscular Diaz-Manera, Jordi Fernandez-Torron, Roberto LLauger, Jaume James, Meredith K Mayhew, Anna Smith, Fiona E Moore, Ursula R Blamire, Andrew M Carlier, Pierre G Rufibach, Laura Mittal, Plavi Eagle, Michelle Jacobs, Marni Hodgson, Tim Wallace, Dorothy Ward, Louise Smith, Mark Stramare, Roberto Rampado, Alessandro Sato, Noriko Tamaru, Takeshi Harwick, Bruce Rico Gala, Susana Turk, Suna Coppenrath, Eva M Foster, Glenn Bendahan, David Le Fur, Yann Fricke, Stanley T Otero, Hansel Foster, Sheryl L Peduto, Anthony Sawyer, Anne Marie Hilsden, Heather Lochmuller, Hanns Grieben, Ulrike Spuler, Simone Tesi Rocha, Carolina Day, John W Jones, Kristi J Bharucha-Goebel, Diana X Salort-Campana, Emmanuelle Harms, Matthew Pestronk, Alan Krause, Sabine Schreiber-Katz, Olivia Walter, Maggie C Paradas, Carmen Hogrel, Jean-Yves Stojkovic, Tanya Takeda, Shin’ichi Mori-Yoshimura, Madoka Bravver, Elena Sparks, Susan Bello, Luca Semplicini, Claudio Pegoraro, Elena Mendell, Jerry R Bushby, Kate Straub, Volker Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials |
title | Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials |
title_full | Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials |
title_fullStr | Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials |
title_full_unstemmed | Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials |
title_short | Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials |
title_sort | muscle mri in patients with dysferlinopathy: pattern recognition and implications for clinical trials |
topic | Neuromuscular |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166612/ https://www.ncbi.nlm.nih.gov/pubmed/29735511 http://dx.doi.org/10.1136/jnnp-2017-317488 |
work_keys_str_mv | AT diazmanerajordi musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT fernandeztorronroberto musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT llaugerjaume musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT jamesmeredithk musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT mayhewanna musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT smithfionae musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT mooreursular musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT blamireandrewm musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT carlierpierreg musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT rufibachlaura musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT mittalplavi musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT eaglemichelle musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT jacobsmarni musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT hodgsontim musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT wallacedorothy musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT wardlouise musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT smithmark musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT stramareroberto musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT rampadoalessandro musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT satonoriko musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT tamarutakeshi musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT harwickbruce musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT ricogalasusana musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT turksuna musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT coppenrathevam musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT fosterglenn musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT bendahandavid musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT lefuryann musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT frickestanleyt musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT oterohansel musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT fostersheryll musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT pedutoanthony musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT sawyerannemarie musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT hilsdenheather musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT lochmullerhanns musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT griebenulrike musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT spulersimone musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT tesirochacarolina musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT dayjohnw musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT joneskristij musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT bharuchagoebeldianax musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT salortcampanaemmanuelle musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT harmsmatthew musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT pestronkalan musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT krausesabine musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT schreiberkatzolivia musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT waltermaggiec musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT paradascarmen musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT hogreljeanyves musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT stojkovictanya musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT takedashinichi musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT moriyoshimuramadoka musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT bravverelena musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT sparkssusan musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT belloluca musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT sempliciniclaudio musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT pegoraroelena musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT mendelljerryr musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT bushbykate musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT straubvolker musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials AT musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials |